• Question: This study describes the current use, management, and safety of nitric oxide administered with integrated delivery devices for pulmonary hypertension after cardiac surgery and persistent pulmonary hypertension of the newborn.
New Modalities for the Administration of Inhaled Nitric Oxide in Intensive Care Units After Cardiac Surgery or for Neonatal Indications: A Prospective Observational Study I nhaled nitric oxide (iNO) induces selective pulmonary vasodilation in cases of pulmonary hypertension (PH) without producing systemic hypotension. 1 It has been largely used in Europe since 1992, 2 and obtained the status of drug in France in 2001 and in Belgium in 2008. The European market authorizations (MA) defined 2 labeled indications: persistent PH of the newborn (PPHN) and treatment of PH related to cardiac surgery. Both indications have been well described in the scientific literature and have benefited from European recommendations 3, 4 in 2005 about pharmacology, combination with other treatments, monitoring, and delivery. In France and Belgium, many centers administer iNO in a continuous mode through a pressure regulator and flowmeter; this is done both with and without monitoring of NO and NO 2 concentrations. Integrated devices for administration and monitoring have recently been made available in these countries but are used in only one-third of the centers providing iNO therapy.
Despite the absence of any evidence of improvement in outcome 5 except for PPHN and congenital heart disease, [6] [7] [8] iNO has become a standard of care for PH in many intensive care units (ICUs), through selective pulmonary vasodilation and a safe pharmacological profile. 9 Otherwise, few small randomized control trials have compared the efficiency of iNO in PH with other drugs such as prostaglandins or phosphodiesterase inhibitors. [10] [11] [12] Some iNO indications, such as perioperative PH in cardiac surgery, are recognized by the MA in Europe but are off-label in the United States. A recent propensity matched-cohort study 13 and systematic review and meta-analysis 14, 15 confirmed that iNO for acute respiratory distress syndrome resulted in a transient improvement in oxygenation but did not reduce mortality and could increase renal impairment. These off-label indications in Europe were not the subject of this study.
Because this is a postapproval study, recruited patients must follow the specifications of MA and only the labeled indications of iNO in Europe were studied. The aim of this study was to describe in neonatal, pediatric, and adult ICUs the current use of iNO with integrated delivery devices in real life for the indications of PPHN and perioperative PH in cardiac surgery. The main objectives were to characterize the profile of patients, the overall management of iNO treatment, the occurrence of adverse events (AEs), and to describe the gap with guidelines because no recent and exhaustive data are reported. Furthermore, this is the first study describing the use of iNO with a new generation of integrated delivery and monitoring device in daily practice. These descriptive data should improve iNO therapy management in ICU and provide updated data for future studies.
METHODS
The POSITIVE (Prospective Observational Study on the use of Inhaled NO administered Through an Integrated deliVEry and monitoring device) study is a multicenter, prospective, observational cohort study held in France and in Belgium and conducted during 1 year in adult, pediatric, and neonatal ICU. Independent French and Belgian ethics committees approved the protocol and data collection was authorized by the National Commission for Informatics and Liberties. All patients or legal representatives received the study information. According to current national legislation for observational studies in France, the ethic committee waived the need for written informed consent and required only a nonopposition to participation. Written informed consent was obtained from all patients or legal representative in Belgium. This article adheres to the applicable Enhancing the QUAlity and Transparency Of health Research (EQUATOR) guidelines. The objectives and methods of the study were designed before patient enrollment, but this study has been retrospectively registered on Clinical Trials website with the number NCT02821156 by Philippe Pouard as principal investigator on May 20, 2016.
Study Population
The cohort was studied in 12 investigational centers in France and 2 in Belgium, including 6 cardiac adult centers, 4 pediatric cardiac centers, and 4 neonatal ICU equipped with EZ-KINOX (EKU Elektronik GmbH, Leiningen, Germany), an integrated NO delivery and monitoring device. EZ-KINOX was used in this study because this device was the first one available in our countries which fulfilled all the specifications required by the European Medicines Agency. This device allows sequential administration of NO, measurement of NO and NO 2 concentrations on the inspiratory limb of the ventilator, and automatic switch from empty to full cylinder, with the same features as INOmax delivery systems (INOmax DSIR or INOvent) which meet Food and Drug Administration guidelines. Furthermore, this device allows the measurement of NO and NO 2 in ambient air. This allows for surveillance of high ambient NO and NO 2 concentrations which may be associated with delivery via high-flow nasal cannula and which may pose a safety risk for caregivers. Participating sites were ICUs trained for the administration of iNO delivered by EZ-KINOX. Perioperative PH was defined by a mean pulmonary arterial pressure (PAP) above 25 mm Hg at rest. 16 The decision to initiate iNO therapy and the choice of dose were at the discretion of the clinician in charge of the patient according to current recommendations on PH management in neonatology or perioperative cardiac surgery before (ie, in the operating room) or after ICU admission. The management in ICU of PH treatment, ventilation mode, or weaning process was not protocolized and followed routine medical care of each center.
Included patients met the following inclusion criteria: (1) newborns ≥34 weeks of gestational age experiencing hypoxic respiratory failure associated with PH; (2) or patients presenting perioperative PH associated with cardiac surgery; (3) patients treated with iNO delivered with EZ-KINOX.
Patients who met at least one of the following criteria could not be included in the study: (1) newborns dependent on a right-to-left shunt; (2) infants with a hemodynamically significant patent ductus arteriosus; and (3) newborns with glucose-6-phosphate dehydrogenase deficiency. Européenne marked delivery and monitoring device provides reliable, constant, and accurate sequential administration of iNO regardless of the patient age, from newborns to adults and continuous NO and NO 2 monitoring. The device includes alarms to alert in case of NO cessation, NO overdose (to detect NO accumulation, threshold arbitrarily set at 2 ppm above the expected dose), or increased inspiratory NO 2 value (>0.5 ppm) for early detection of potentially toxic NO 2 production. This system is compatible with most of ventilation modes (invasive and noninvasive) and ventilators, to which it is connected either directly (via a RS232 interface for compatible ventilators) or through a flow sensor for synchronization with mechanical ventilation.
Study Treatment

Data Collection
The characteristics of included patients, the diagnosis of PH, and the following parameters were prospectively recorded on case report forms and AE forms by physicians: description of iNO administration with dosage and treatment duration, associated ventilation mode, weaning procedures, and occurrence of a rebound effect (defined by the association of abrupt increase of pulmonary pressure and desaturation). Monitoring associated with iNO administration, concomitant pulmonary vasodilator treatments, safety data, ICU length of stay, and ICU mortality were also collected. All forms were verified by a monitoring team and analyzed by an independent committee.
Statistical Analysis
Statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC). Analyses were only descriptive and expressed as mean and standard deviation or median and interquartile range (25th, 75th percentile) whenever applicable for each subgroup of patients. The 3 subgroups of patients were defined as neonates for PPHN patients, children for pediatric cardiac surgery patients with postoperative PH, and adults for patients with PH after adult cardiac surgery. Parameters collected were summarized descriptively without comparison between subgroups due to the lack of clinical relevance. Safety was evaluated by describing the occurrences of AE, globally and by subgroup of patients, using percentages and 2-sided exact ClopperPearson 95% confidence intervals (CIs).
The duration of the study was planned for 1 year of recruitment to limit the likelihood of changes of current practices in iNO usage. Sample size estimation was based on feasibility considerations. Before the study, it was estimated that a maximal number of 250 patients could be included in 1 year. This maximum sample size allowed the reporting of a 2-sided 95% CI of any event occurring with a frequency of 5% of (2.8%-8.7%) which is narrow enough to adequately address the research question.
RESULTS
Patient Characteristics
A total of 239 consecutive patients were enrolled in 1 year from September 2014 to September 2015. One patient did not sign consent, and 2 presented noninclusion criteria. Therefore 236 patients were included: 38 neonates with PPHN (16.1%), 81 children (34.3%), and 117 adult patients (49.6%) with PH after cardiac surgery. Baseline demographics and characteristics of the 3 groups of patients are described in Table 1 . The diagnosis process of PH before the initiation of iNO included Doppler and color-Doppler, 2-dimensional echocardiography, and/or measurement of the PAP through a pulmonary artery catheter ( Table 2 ). All the patients had a mean PAP >25 mm Hg.
In the adult group, the 4 main circumstances of PH were mitral valve surgery, combined cardiac surgery for acquired cardiac disease, heart transplantation, and left ventricular assist device implantations. In pediatric cardiac surgery, neonatal surgery and cavopulmonary connections were the main indications for iNO administration. PPHN was mainly associated with respiratory distress syndrome, meconium aspiration syndrome, and diaphragmatic hernia. The iNO was initiated before ICU admission (Table 3) in adult patients in the operating room (57%), and in PPHN patients in the delivery room (38.9%), but rarely among pediatric cardiac patients (12.7%). Patients being treated with iNO were transported to ICU without interruption of this treatment.
Inhaled NO Therapy
Adults received a median initial iNO dose (10 ppm; 25th, 75th percentile: 10, 15 ppm) approximately half of the dose in neonates (17 ppm; 25th, 75th percentile: 11, 20 ppm) and children (20 ppm; 25th, 75th percentile: 18, 20 ppm). The iNO administration was gradually weaned on a median of 3.1 days in newborns, 3.9 days in children, and 3.8 days in adults (Table 3) . At the onset of iNO delivery with EZ-KINOX, most of the patients were ventilated using a controlled ventilation mode in 78.9%, 92.6%, and 94.0% of neonates, children, and adults, respectively (Table 1) . Highfrequency oscillatory ventilation was used in 15.8% of neonates. Throughout the course of delivery, the ventilation mode was switched to spontaneous ventilation or noninvasive ventilation including nasal high-flow cannula in 7.4%, 80.6%, and 39.3% in neonates, children, and adults, respectively. The connections between EZ-KINOX and ventilators were a RS232 interface in 52% or a flow sensor in 26% of cases, allowing synchronization with ventilation, and a manual mode was used in 22%.
Other pulmonary vasodilators were combined before, during, and after inhalation of NO, including milrinone, sildenafil, and/or levosimendan (Figure) mainly for the pediatric cardiac surgery population (maximum rate of 84%). The dose was gradually decreased before definitive withdrawal of iNO in 85% of cases and the median lowest doses of iNO were 3 ppm in neonates, 5 ppm in children and adults (Table 3) . The NO 2 generated by contact between NO and oxygen during iNO administration was above 0.5 ppm in 17% of pediatric cases, 1% of adult cases and never observed in the neonatal population. The monitoring of ambient NO and NO 2 in room air has never shown any increase >0.5 ppm of ambient NO or NO 2 values during the study, guaranteeing the safety of the professionals working around the patient.
Adverse Events
Outcomes
The main reason for definitive discontinuation of iNO therapy was a sufficient clinical effect with successful weaning 
DISCUSSION
After several decades of use, iNO is currently considered as a standard of care in many countries for PH in cardiac surgery and PPHN. [6] [7] [8] [9] 17, 18 Considering diversity in age, PH level, circumstances for treatment, and ventilation mode, this prospective study described the current ICU usage of iNO in specialized neonatal and cardiac centers.
Because of the potential side effects 19 and the cost 20 of the drug, the iNO indications should be carefully selected in case of prolonged use. Abrupt discontinuation of iNO delivery, for any reason can cause a rebound effect with acute PH [21] [22] [23] and iNO overdose can lead to toxic NO 2 and methemoglobin production. 23 Therefore, delivery systems need to be reliable for iNO delivery and NO/NO 2 monitoring. 24, 25 New generations of NO delivery devices meet these requirements and may prevent any discontinuation of drug delivery during transport or cylinders exchange. This is the first study reporting clinical use of these devices in Europe. The modes of ventilation during NO therapy differed between the 3 groups and the treatment times. Invasive modes of ventilation were the most common at the initiation of the treatment and high-frequency oscillatory ventilation was reserved to PPHN. During the weaning phase, ventilation modes were less invasive or controlled, especially in cardiac patients with spontaneous ventilation or noninvasive ventilation (including nasal high-flow therapy) for most of them. In this study, the new generation of devices allowed easy adaptation to different modes of ventilation.
Some specificities were observed regarding the different population groups. In this study, the diagnosis of PH was always performed by echocardiography in neonates experiencing PPHN as described in literature, [26] [27] [28] and iNO therapy was often started before ICU admission either in the delivery room or during transport. Therefore, the delivery system and NO cylinders should be adapted to be used safely during transport. In pediatric cardiac surgery, PH was often diagnosed before the surgical procedure by echocardiography and/or direct PAP measurement by catheterization 29 and iNO was mainly initiated in ICU after the procedure. In this group, the mean PAP level (27.2 ± 14.8 mm Hg for this group) was lowered in case of cavopulmonary connection where iNO was used to reduce the transpulmonary gradient more than to reverse a PH crisis. 3 Consistent with published data, 30 iNO was almost always combined with oral sildenafil. In this population, despite a higher dose, the occurrence of adverse effects was very low. The specificities of the adult population were the necessity for iNO administration in the operating room before ICU admission in almost 60% of cases, and the limited requirement of additional pulmonary vasodilators. Surprisingly, the initial dose of NO was about 10 ppm without the need to increase the dose during treatment. This is less than the dose mentioned in the American and European recommendations which allow a dose up to 40 ppm. 4 Only 3 patients, 2.6% of the adult group, did not respond to NO therapy and none in neonatal and pediatric groups. Some reports show a 20% rate of nonresponders. 31, 32 The low rate of nonresponders may result from the strict use of iNO in labeled indications and/or the synergistic effect of the combination with other pulmonary vasodilators.
For the 3 populations, the results show that the weaning procedure included a stepwise progressive discontinuation of iNO delivery, avoiding a rebound effect of PH characterized by an acute increase of pulmonary vascular resistance, hypoxia, and hemodynamic impairment and caused by transient depletion of intrinsic cyclic guanosine monophosphate. Kageyama et al 33 showed that the final concentration of <2 ppm contributes to successful discontinuation of iNO therapy in pediatric patients after cardiac surgery. As suggested by Namachivayam et al, 30 combination with other pulmonary vasodilators may prevent the occurrence of a rebound effect. In a recent expert consensus on pediatric PH, 34 oral sildenafil is mentioned as reasonable to facilitate weaning from iNO. The low PH rebound rate observed in our study (1.2%) could result from the wide application of 1 or 2 of these strategies. In this study, iNO was administered through a consistent delivery device and 82.4% of the patients did not experience any AEs. The most common safety concern was NO 2 formation in pediatric cardiac surgery which can be explained by the high fraction of inspired oxygen usually required after pediatric cardiac procedures. 35 Methemoglobin excess is one of the main side effect observed in the neonatal population; however, the reduction of the iNO dose allowed rapid recovery without clinical impact. This issue, also described in children with congenital heart disease, 36 was not observed in our study but methemoglobin monitoring was not systematically performed in pediatric and adult ICU as requested in the recommendations. 4 This practice should be maintained especially for highest iNO doses.
Compared with the former retrospective survey conducted in 1997 in 21 European countries and based only on questionnaires, 8 iNO therapy has changed in several aspects. The 1997 survey was conducted before the establishment of clear recommendations. In 1997, 62% of the physicians did not consider the PAP threshold, and administered more than 40 ppm in 43% of cases compared to 20 ppm or less in all cases of our observations. Moreover, 51% of cases received iNO in a continuous mode throughout the respiratory cycle, whereas in the POSITIVE study, iNO was administered during the inspiratory phase (78% of synchronized connections to ventilators). In France and Belgium, the cost of iNO is based on the volume of gas used, and therefore synchronization of gas delivery with invasive or noninvasive mechanical ventilation would be expected to reduce waste of this expensive gas compared to bolus delivery. Differences in indications (in 1997, the main indication for iNO therapy was acute respiratory distress syndrome) and in the modes of administration may probably explain a better response to iNO therapy (10%-20% nonresponder vs 0%-2.6%) and a huge decrease of the occurrence of incidents and complications (9% excessive bleeding vs 0%; 6% acute pulmonary edema vs 0%; 20% rebound effect vs 1.2%-3.4%).
Study Limitations
This study provides a snapshot in time and presents several bias and confounding effects such as representability of the sample and selection bias. Main limitations are the selection of centers using EZ-KINOX device which did not represent most of NO users and the strictly restriction of MA indication (excluding off-label usage of the product in Europe). The results may not be generalizable to other NO delivery systems and to these off-label indications. Of note, despite a common use especially in the pediatric population, the indication of iNO for PH in cardiac surgery is off-label in the United States due to a lack of definitive evidence. 37 The heterogeneity of practices in the use and management of iNO was another limitation. However, the objective of this observational study was to describe current practices and the only constraint in the study protocol was to use the EZ-KINOX device. Data on hemodynamic and echocardiography were not required after initiation of iNO therapy and the assessment of "sufficient clinical effect" or "lack of efficacy" could be subjective but are the reflect of medical practices.
CONCLUSIONS
This large prospective study in 236 patients describes the current use pattern of iNO and confirms the safety of iNO in the study population with a low rate of rebound effect. Gradually withdrawal of NO and combination with other pulmonary vasodilators are current practices in this population. Confidence in the delivery and monitoring devices is likely to reduce the maximum administered dose of iNO and to secure transportation and change of NO cylinders without discontinuation. While there have been improvements in delivery and monitoring of iNO therapy within the last 2 decades, further controlled randomized trials and international registry data will be needed to define appropriate indications for use of iNO and to refine the current guidelines. E
